ICH Good Clinical Practice

ICH Good Clinical Practice
Name	ICH Good Clinical Practice
Abbreviation	ICH GCP
Established	1996
Parent organization	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
Scope	Clinical trials for medicinal products

ICH Good Clinical Practice

ICH Good Clinical Practice is an international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials that involve human subjects. It was developed through collaboration among regulatory and industry bodies to harmonize requirements across regions and to protect trial participants while ensuring data credibility. The guideline informs regulatory submissions and is referenced by authorities and institutions worldwide.

Background and Scope

The guideline originated from discussions among United States Food and Drug Administration, European Medicines Agency, Ministry of Health, Labour and Welfare (Japan), World Health Organization, European Commission, Council for International Organizations of Medical Sciences, and industry groups such as International Federation of Pharmaceutical Manufacturers & Associations and Pharmaceutical Research and Manufacturers of America. Its drafting process involved scientific committees and expert working groups that included members from Food and Drug Administration (United States), Medicines and Healthcare products Regulatory Agency, Health Canada, PMDA (Japan), and representatives tied to regulatory frameworks like the European Clinical Trials Directive and laws such as the Food, Drug, and Cosmetic Act. The scope encompasses clinical trials of investigational medicinal products intended for regulatory submission in regions represented by the International Council for Harmonisation, including regions covered by ICH E6, and interfaces with documents like Declaration of Helsinki and standards from International Organization for Standardization.

Key Principles and Ethical Standards

ICH GCP enshrines principles that align with foundational documents involving figures and bodies such as Helsinki Declaration signatories, ethics committees like those modeled after the Nuremberg Code era reforms, and institutional arrangements found at National Institutes of Health. Core tenets require respect for participant rights echoed in legal instruments such as the European Convention on Human Rights and oversight by independent review bodies akin to Institutional Review Board (United States) and Research Ethics Committee (United Kingdom). Responsibilities for informed consent reference practices associated with clinical trials conducted under oversight by World Health Organization and reporting expectations linked to submissions made to authorities like European Medicines Agency and United States Food and Drug Administration.

Organization and Responsibilities

The guideline delineates roles for stakeholders including sponsors, investigators, monitors, and ethics committees. Sponsors may be companies like Pfizer, Novartis, Roche, or institutions comparable to Johns Hopkins University and Mayo Clinic. Investigators often affiliate with academic centers such as Harvard Medical School, University of Oxford, Karolinska Institutet, or hospitals like Massachusetts General Hospital and Royal Free Hospital. Monitoring and data custodianship involve contract research organizations akin to Quintiles IMS and quality units influenced by standards from bodies such as European Medicines Agency and International Council for Harmonisation. Regulatory interactions occur with agencies including Food and Drug Administration (United States), Health Canada, Therapeutic Goods Administration, and national ministries like Ministry of Health, Labour and Welfare (Japan).

Clinical Trial Conduct and Documentation

Detailed requirements cover protocol design, investigator brochures, case report forms, and trial master files. Protocols often reference scientific contexts from institutions like National Institutes of Health and review practices exemplified by Cochrane Collaboration systematic approaches. Documentation standards intersect with pharmacovigilance systems such as those administered by European Medicines Agency, Vigilance systems used by companies like AstraZeneca, and submission dossiers prepared for regulatory pathways like those under the European Union Clinical Trials Regulation. Data handling practices reflect guidance from bodies including International Organization for Standardization and reporting conventions influenced by journals such as The New England Journal of Medicine and The Lancet.

Quality Assurance and Monitoring

Quality systems under ICH GCP promote monitoring, auditing, and corrective action processes comparable to compliance programs at multinational firms like GlaxoSmithKline and academic audit models at University College London. Risk-based monitoring approaches have been adopted following recommendations from experts linked to Food and Drug Administration (United States) guidance discussions and industry consortia including TransCelerate Biopharma. Audits may be performed by regulators such as European Medicines Agency and internal audit units within institutions like Roche and Novartis. Quality assurance also incorporates training and certification frameworks paralleled by programs at Duke University, Stanford University School of Medicine, and professional societies such as the Drug Information Association.

Compliance, Regulatory Adoption, and Global Impact

ICH GCP has been adopted, referenced, or adapted by regulatory authorities worldwide, influencing legislation and guidance in jurisdictions overseen by European Medicines Agency, Food and Drug Administration (United States), Health Canada, Therapeutic Goods Administration, and Ministry of Health, Labour and Welfare (Japan). Its impact is seen in multinational trials sponsored by companies like Johnson & Johnson and consortia such as International AIDS Vaccine Initiative, and in academic multicenter studies coordinated by networks like National Institutes of Health. Ongoing revisions and addenda involve stakeholders from agencies including European Commission and organizations like World Health Organization, and align with parallel initiatives such as Good Manufacturing Practice and pharmacovigilance frameworks under the Council for International Organizations of Medical Sciences.

Category:Clinical research